MBMichael C. Boyle

Michael C. Boyle

*This is an algorithmically generated author record based on publicly available information.

Michael C. Boyle has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Methods, Supplementary Tables 1 - 11, and Supplementary Figures 1-9 from Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia

    by Bettina Brauchle, Rebecca L. Goldstein, Christine M. Karbowski, Anja Henn, Chi-Ming Li, Veit L. Bücklein, Christina Krupka, Michael C. Boyle, Priya Koppikar, Sascha Haubner, et al.

    Supplementary Methods. Supplementary Table 1 - Key Resources Including Sources of Biological Samples, Antibodies, and Key Reagents. Supplementary Table 2 -Correlation of FLT3 Expression Levels With Disease Characteristics at Initial Diagnosis. Supplementary Table 3 - Summary of Human Nonimmune Tissues Positive for FLT3 mRNA and/or Protein Expression in At Least One Platform. Supplementary Table 4. Cerebellum FLT3 RNA Analysis. Supplementary Table 5 - Binding Affinities of Experimental FLT3 BiTE® Molecule and AMG 427. Supplementary Table 6 - Cell Line Characterization, Cytotoxicity, and T-Cell Activation (Human). Supplementary Table 7 - Cynomolgus Monkey Pharmacokinetics for Experimental FLT3 BiTE® Molecule. Supplementary Table 8 - Cynomolgus Monkey Pharmacokinetics for AMG 427. Supplementary Table 9 - Cynomolgus Monkey FLT3 Primer and Probe Sequences. Supplementary Table 10 - Patient Characteristics. Supplementary Table 11 - Mass Spectrometry Results. Supplementary Figure 1 - Additional flow cytometry expression analysis for acute myeloid leukemia (AML) and healthy donor (HD) bone marrow (BM). Supplementary Figure 2 - Analysis of FLT3 expression on normal human bone marrow. Supplementary Figure 3 - Analysis of FLT3 transcript and protein in cerebellum revealed truncated transcripts. Supplementary Figure 4 - In vitro characterization of FLT3 BiTE® molecules. Supplementary Figure 5 - Experimental FLT3 BiTE® molecule activity in vivo. Supplementary Figure 6 - FLT3 BiTE® molecule in vitro activity with cynomolgus monkey effector cells. Supplementary Figure 7 - FLT3 expression in cynomolgus monkey blood and bone marrow. Supplementary Figure 8 - AMG 427 pharmacodynamics in cynomolgus monkey. Supplementary Figure 9 - (A) Representative populations of T cells (CD2+) and AML cells (CD33+) over time from a responder (Patient 4; Figure 6A). (B) PD-1 expression on CD3+ cells from a T-cell-dependent cellular cytotoxicity (TDCC) of human pan T cells co-cultured 5:1 with MV4-11 cells for 48 hours assessed by flow cytometry.

  • Open Access

    Supplementary Methods, Supplementary Tables 1 - 11, and Supplementary Figures 1-9 from Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia

    by Bettina Brauchle, Rebecca L. Goldstein, Christine M. Karbowski, Anja Henn, Chi-Ming Li, Veit L. Bücklein, Christina Krupka, Michael C. Boyle, Priya Koppikar, Sascha Haubner, et al.

    Supplementary Methods. Supplementary Table 1 - Key Resources Including Sources of Biological Samples, Antibodies, and Key Reagents. Supplementary Table 2 -Correlation of FLT3 Expression Levels With Disease Characteristics at Initial Diagnosis. Supplementary Table 3 - Summary of Human Nonimmune Tissues Positive for FLT3 mRNA and/or Protein Expression in At Least One Platform. Supplementary Table 4. Cerebellum FLT3 RNA Analysis. Supplementary Table 5 - Binding Affinities of Experimental FLT3 BiTE® Molecule and AMG 427. Supplementary Table 6 - Cell Line Characterization, Cytotoxicity, and T-Cell Activation (Human). Supplementary Table 7 - Cynomolgus Monkey Pharmacokinetics for Experimental FLT3 BiTE® Molecule. Supplementary Table 8 - Cynomolgus Monkey Pharmacokinetics for AMG 427. Supplementary Table 9 - Cynomolgus Monkey FLT3 Primer and Probe Sequences. Supplementary Table 10 - Patient Characteristics. Supplementary Table 11 - Mass Spectrometry Results. Supplementary Figure 1 - Additional flow cytometry expression analysis for acute myeloid leukemia (AML) and healthy donor (HD) bone marrow (BM). Supplementary Figure 2 - Analysis of FLT3 expression on normal human bone marrow. Supplementary Figure 3 - Analysis of FLT3 transcript and protein in cerebellum revealed truncated transcripts. Supplementary Figure 4 - In vitro characterization of FLT3 BiTE® molecules. Supplementary Figure 5 - Experimental FLT3 BiTE® molecule activity in vivo. Supplementary Figure 6 - FLT3 BiTE® molecule in vitro activity with cynomolgus monkey effector cells. Supplementary Figure 7 - FLT3 expression in cynomolgus monkey blood and bone marrow. Supplementary Figure 8 - AMG 427 pharmacodynamics in cynomolgus monkey. Supplementary Figure 9 - (A) Representative populations of T cells (CD2+) and AML cells (CD33+) over time from a responder (Patient 4; Figure 6A). (B) PD-1 expression on CD3+ cells from a T-cell-dependent cellular cytotoxicity (TDCC) of human pan T cells co-cultured 5:1 with MV4-11 cells for 48 hours assessed by flow cytometry.

  • Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia

    by Bettina Brauchle, Rebecca L. Goldstein, Christine M. Karbowski, Anja Henn, Chi-Ming Li, Veit L. Bücklein, Christina Krupka, Michael C. Boyle, Priya Koppikar, Sascha Haubner, et al.

    Despite advances in the treatment of acute myeloid leukemia (AML), novel therapies are needed to induce deeper and more durable clinical response. Bispecific T-cell Engager (BiTE) molecules, which redirect patient T cells to lyse tumor cells, are a clinically validated modality for hematologic malignancies. Due to broad AML expression and limited normal tissue expression, fms-related tyrosine kinase 3 (FLT3) is proposed to be an optimal BiTE molecule target. Expression profiling of FLT3 was performed in primary AML patient samples and normal hematopoietic cells and nonhematopoietic tissues. Two novel FLT3 BiTE molecules, one with a half-life extending (HLE) Fc moiety and one without, were assessed for T-cell–dependent cellular cytotoxicity (TDCC) of FLT3-positive cell lines in vitro, in vivo, and ex vivo. FLT3 protein was detected on the surface of most primary AML bulk and leukemic stem cells but only a fraction of normal hematopoietic stem and progenitor cells. FLT3 protein detected in nonhematopoietic cells was cytoplasmic. FLT3 BiTE molecules induced TDCC of FLT3-positive cells in vitro, reduced tumor growth and increased survival in AML mouse models in vivo. Both molecules exhibited reproducible pharmacokinetic and pharmacodynamic profiles in cynomolgus monkeys in vivo, including elimination of FLT3-positive cells in blood and bone marrow. In ex vivo cultures of primary AML samples, patient T cells induced TDCC of FLT3-positive target cells. Combination with PD-1 blockade increased BiTE activity. These data support the clinical development of an FLT3 targeting BiTE molecule for the treatment of AML.